Bausch + Lomb Corporation - BLCO STOCK NEWS

Bausch + Lomb and Heidelberg Engineering have launched the SeeLuma™ Fully Digital Surgical Visualization Platform, enhancing surgical procedures for ophthalmic surgeons. The platform provides superior visualization compared to existing surgical microscopes, featuring heads-up 3D monitors, multiple digital display options, and an intuitive interface. First launched in the United States and Western Europe, SeeLuma aims to improve surgical outcomes through its ergonomic design and educational features. The high-quality imaging capabilities, including 4K resolution and enhanced anatomical landmark visualization, position SeeLuma as a key tool for modern ophthalmic surgeries. This innovation reflects the companies' commitment to advancing surgical technology and improving patient care.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced on April 12, 2023, the appointments of Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President of Ophthalmic Pharmaceuticals, effective April 24, 2023. Both will join the executive management team. Christina Ackermann will step down from her role and leave the company on April 28, 2023. Brent Saunders, the company's CEO, expressed confidence in Bailey and Stewart's ability to create value and ensure long-term success for Bausch + Lomb. Bailey returns after 18 years, while Stewart comes with extensive experience from AbbVie, focusing on enhancing the company’s prescription medicines and ophthalmic product portfolio.

Bausch + Lomb Corporation (BLCO) and Novaliq GmbH announced the publication of Phase 3 trial results for NOV03 (perfluorohexyloctane), a potential treatment for dry eye disease linked to Meibomian gland dysfunction. The trial met primary efficacy endpoints, demonstrating significant improvements in both corneal staining and dryness scores at 8 weeks. NOV03, which targets excessive tear evaporation, was well tolerated with minor adverse events. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023, with further data expected from ongoing studies, marking an important step for addressing the needs of millions suffering from this condition.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) reported its fourth-quarter and full-year 2022 financial results with revenues of $996 million for Q4 and $3.768 billion for the year, showing organic revenue growth of 5% across all segments. The company faced a net loss of $1 million in Q4 compared to a $51 million profit in the same period the previous year. Adjusted EBITDA decreased to $181 million for Q4 and $720 million for the year. Despite foreign exchange impacts, the Vision Care and Surgical segments performed well, with notable product launches and a focus on strategic partnerships. Brent Saunders was appointed as the new CEO effective March 6, 2023.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has appointed Brent Saunders as CEO and Chair of the Board, effective March 6, 2023. He succeeds Joseph C. Papa, who steps down as CEO and director. Saunders, who previously served as CEO from 2010 to 2013, brings over 25 years of health care leadership experience. The Board expressed confidence in Saunders' ability to guide the company through its separation from Bausch Health. During his advisory role beginning February 16, 2023, he collaborated closely with Papa to ensure a smooth transition. The company focuses on advancing eye health and developing innovative treatments.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced a new social media campaign titled ‘What Sight Inspires You’, aimed at raising awareness for Age-related Macular Degeneration (AMD) during AMD Awareness Month in February. The campaign focuses on personal stories from the SightMatters community, which supports individuals living with AMD. Approximately 16 million Americans suffer from this condition, with numbers projected to rise. Although there is no cure, lifestyle changes and collaboration with eye doctors can help manage AMD risks. This initiative reflects Bausch + Lomb's commitment to eye health and supporting patients.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) and Modulight Corporation announced FDA approval for the ML6710i photodynamic laser. This laser is approved for use with Bausch + Lomb's VISUDYNE® therapy, targeting predominantly classic subfoveal choroidal neovascularization caused by Age-related Macular Degeneration (AMD). The ML6710i, designed for easy use and transport, will be available in the first half of 2023. This innovation addresses a significant unmet need in photodynamic therapy, allowing eye care professionals to treat patients more effectively.

Bausch + Lomb Corporation (BLCO) will announce its fourth-quarter and full-year 2022 financial results on February 22, 2023. The company will hold a conference call at 8:00 a.m. ET to discuss the financial outcomes and provide an update on business developments. Interested parties can access the call via web link or dial-in options for both North American and international participants. Replay details will also be available until March 8, 2023.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has acquired AcuFocus, a leader in ophthalmic medical devices, enhancing its surgical portfolio with the IC-8 Apthera intraocular lens (IOL). This IOL, approved by the FDA in July 2022, is the first small aperture non-toric EDOF IOL, catering to cataract patients with up to 1.5 diopters of astigmatism. The global premium cataract IOL market is projected to grow at a CAGR of approximately 13% from 2022 to 2027. With 94 million people affected by cataracts worldwide, Bausch + Lomb aims to offer innovative solutions to meet unmet medical needs, driving long-term growth.